Back to top
more

Madrigal Pharmaceuticals (MDGL)

(Delayed Data from NSDQ)

$223.29 USD

223.29
808,191

-6.29 (-2.74%)

Updated May 28, 2024 04:00 PM ET

After-Market: $223.32 +0.03 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MDGL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Madrigal Pharmaceuticals, Inc. [MDGL]

Reports for Purchase

Showing records 101 - 120 ( 184 total )

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 101

11/08/2018

Company Report

Pages: 7

3Q Recap: Phase 3 NASH Study to Start by Early 2019; Looking at Dyslipidemias Too; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 102

11/07/2018

Company Report

Pages: 6

3Q18 - Clever Beavers; Affirm Buy

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 103

10/24/2018

Industry Report

Pages: 7

Healthcare - NASH Weekly: Dealing with the Bears at AASLD

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 104

10/05/2018

Industry Report

Pages: 10

Healthcare - AASLD Nonsense - Sense and the War of FXR Agonists

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 105

10/01/2018

Industry Report

Pages: 4

Healthcare - The Liver Meeting Abstracts Part 1: Our Coverage Universe

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 106

09/26/2018

Daily Note

Pages: 3

MORNING - MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 107

09/25/2018

Industry Report

Pages: 7

NASH Weekly: MDGL vs. VKTX Data Comparison Is Not Apples to Apples

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 108

09/25/2018

Company Report

Pages: 6

How Do Amarin Outcome Data Read Through to MDGL?

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 109

09/21/2018

Industry Report

Pages: 3

Healthcare - Love NASH, Mark Your Calendar for October 17

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 110

09/19/2018

Industry Report

Pages: 5

Our Perspectives on VKTX Data and Derivatives for MDGL, GNFT

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 111

09/14/2018

Industry Report

Pages: 5

Healthcare -NASH Weekly: Strong NASH Bull Market Ahead

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 112

08/31/2018

Industry Report

Pages: 6

Healthcare - NASH Weekly: Lesson Learned This Summer

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 113

08/16/2018

Industry Report

Pages: 9

Healthcare -Hug the Bear or Tackle the Bear Series

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 114

08/08/2018

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 115

08/08/2018

Company Report

Pages: 6

2Q18 - Phase 3 Execution on the Table Doesn''t Mean M-A Is Off

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 116

08/08/2018

Company Report

Pages: 5

2Q Recap: Phase 2 NASH Study Data at AASLD Presidential Plenary in November; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 117

07/13/2018

Industry Report

Pages: 6

Healthcare - Hug the Bear or Tackle the Bear Series: GNFT.PA

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 118

06/29/2018

Industry Report

Pages: 5

Healthcare - NASH Weekly Series: Hug the Bear Or Tackle The Bear

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 119

06/01/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 120

06/01/2018

Industry Report

Pages: 3

Healthcare - NASH Weekly: Come One, Come All

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party